PASG Stock Alert: Halper Sadeh LLC is Investigating Whether Passage Bio, Inc. is Obtaining a Fair Price for its Shareholders

Halper Sadeh LLC is investigating the proposed merger of Passage Bio and Remix Therapeutics. Passage Bio shareholders are expected to own approximately 7% of the combined company upon closing; the notice does not report a lawsuit, transaction outcome, or market reaction.

Analysis

This is a shareholder-rights solicitation, not evidence that a lawsuit has been filed or that the merger terms are defective. The immediate signal for PASG is therefore low: legal headlines can add volatility and create a modest closing-delay overhang, but do not by themselves change the combined company’s economics. The more consequential issue is the stated 7% post-close ownership for current Passage Bio holders: it implies limited participation in future upside and makes the exchange terms, fully diluted share count, and any financing or cash contribution central to assessing value. Those details are not provided here, so neither dilution nor deal fairness can be quantified from this item.

Over the next 1–3 months, monitor for an actual complaint, proxy disclosures, shareholder-vote developments, and any change to closing conditions; an injunction or renegotiation would matter more than further law-firm outreach. Over 6–18 months, the relevant question is whether the combined company can fund and execute its plans—not the solicitation itself. Contrarian read: treating routine investor-rights outreach as a standalone bearish catalyst risks overreacting. No directional trade is justified absent deal terms, PASG’s unaffected price, and closing-risk information.

Key Decisions for Investors

• No trade on this headline alone. Avoid shorting PASG solely on the solicitation; the signal is weak and could fade quickly.
• Before considering a merger-arbitrage or event position, verify the exchange ratio, consideration, fully diluted capitalization, financing needs, shareholder-vote timetable, and closing conditions in the proxy or merger filings.
• Set alerts for an actual complaint, court action, proxy revision, vote delay, or amended deal terms. Reassess exposure if any of these materially increases closing risk.
• Falsification of the low-impact view: a court order or credible filing that delays or blocks closing, or a material adverse revision to consideration or transaction terms.